Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-27T22:30:10.434Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

Published online by Cambridge University Press:  16 April 2020

H.-J. Möller
H.-J. Möller*
Affiliation:
Department of Psychiatry, Ludwig-Maximilians-University, Nussbaum Strasse 7, 80336Munich, Germany
Get access

Abstract

Relapse is one of the key factors in the long-term outcome of schizophrenia. The consequences of relapse are diverse and often unpredictable, and the time to recovery and degree of recovery worsen with each successive relapse. There is now overwhelming evidence that advances in antipsychotic drug treatment have led to significant reductions in the rate of relapse. This review charts the developments that have taken place in antipsychotic therapy from the introduction of depot formulations, through atypical agents, to the development of the first long-acting atypical antipsychotic. Depot formulations of conventional antipsychotics were developed in the 1960s and led to fewer relapses and episodes of hospitalization, compared with oral equivalents. Meta-analysis has confirmed that patients receiving depot antipsychotics experience significantly greater global improvement than those receiving the respective oral agents. Conventional antipsychotics are, however, associated with a range of potentially serious adverse events. The atypical antipsychotics were introduced in the 1990s and have significant advantages over conventional agents with regard to positive and negative symptoms. There is also evidence that atypical agents can reduce the risk of relapse. Importantly, atypical antipsychotics have an improved safety profile compared with older agents, particularly with regard to extrapyramidal symptoms. One disadvantage of atypical agents has been that they are only available in an oral form. The recent development of a long-acting injectable formulation of risperidone means that a new treatment option is available to physicians.

Keywords

SchizophreniaAtypical antipsychoticsConventional antipsychoticsLong-acting injectable formulationRelapse
Type
Review
Information
European Psychiatry , Volume 20 , Issue 5-6 , August 2005 , pp. 379 - 385
Copyright
Copyright ©Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, C.E., Eisenbruch, M.Depot fluphenazine for schizophrenia (Cochrane review). The Cochrane Library, issue 2 Oxford; Update Software; 2001Google Scholar
Adams, C.E., Fenton, M.K., Quraishi, S., David, A.S.Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 2001; 179: 290–299CrossRefGoogle ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004; 65: 267–272CrossRefGoogle Scholar
Bloch, Y., Mendlovic, S., Strupinsky, S., Altshuler, A., Fennig, S., Ratzoni, G.Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J. Clin. Psychiatry 2001; 62: 855–859CrossRefGoogle ScholarPubMed
Arvanitis, L.A., Miller, B.G.Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry 1997; 42: 233–246CrossRefGoogle ScholarPubMed
Babiker, I.E.Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J. Clin. Psychiatry 1987; 48: 94–97Google ScholarPubMed
Barnes, T.R., Curson, D.A.Long-term depot antipsychotics. A risk–benefit assessment. Drug Saf. 1994; 10: 464–479CrossRefGoogle ScholarPubMed
Beasley, , Jr, C.M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S.Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–123CrossRefGoogle ScholarPubMed
Bossie, CA, Lasser, RA, Gharabawi, G. Low or absent pain and injection site effects with long-acting risperidone. San Francisco, CA, USA: Poster presented at the American Psychiatric Association (APA) annual meeting; 2003.Google Scholar
Bouchard, R.H., Merette, C., Pourcher, E., Demers, M.F., Villeneuve, J., Roy-Gagnon, M.H., et al.Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. J. Clin. Psychopharmacol. 2000; 20: 295–304CrossRefGoogle ScholarPubMed
Briffa, D., Meehan, T.Weight changes during clozapine treatment. Aust. NZ J. Psychiatry 1998; 32: 718–721CrossRefGoogle ScholarPubMed
Bristow, M.F., Hirsch, S.R.Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia. Drug Saf. 1993; 8: 136–148CrossRefGoogle Scholar
Brown, C.S., Markowitz, J.S., Moore, T.R., Parker, N.G.Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann. Pharmacother. 1999; 33: 210–217CrossRefGoogle Scholar
Bustillo, J., Lauriello, J., Horan, W., Keith, S.The psychosocial treatment of schizophrenia: an update. Am. J. Psychiatry 2001; 158: 163–175CrossRefGoogle ScholarPubMed
Canuso, C, Lasser, R. Significantly reduced serum prolactin levels following treatment with long-acting risperidone. San Francisco, CA, USA:Poster presented at the American Psychiatric Association (APA) annual meeting; 2003.Google Scholar
Carman, J., Peuskens, J., Vangeneugden, A.Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int. Clin. Psychopharmacol. 1995; 10: 207–213CrossRefGoogle ScholarPubMed
Casey, D.E.Extrapyramidal syndromes. Epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 5Suppl 11996 1–12CrossRefGoogle Scholar
Conley, R.R., Mahmoud, R.A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2001; 158: 765–774CrossRefGoogle ScholarPubMed
Csernansky, J.G., Mahmoud, R., Brenner, R.A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002; 346: 16–22CrossRefGoogle ScholarPubMed
Cunningham Owens, D.G.Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996; 51: 895–930CrossRefGoogle Scholar
Curson, D.A., Barnes, T.R., Bamber, R.W., Platt, S.D., Hirsch, S.R., Duffy, J.C.Long-term depot maintenance of chronic schizophrenic out-patients: the 7-year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br. J. Psychiatry 1985; 146: 469–474Google Scholar
David, A., Quraishi, S.Depot perphenazine decanoate and enanthate for schizophrenia (Cochrane review). The Cochrane Library, issue 2 Oxford: Update Software; 2001.Google Scholar
Davies, A., Adena, M.A., Keks, N.A., Catts, S.V., Lambert, T., Schweitzer, I.Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin. Ther. 1998; 20: 58–71CrossRefGoogle ScholarPubMed
Davis, J.M., Chen, N.Clinical profile of an atypical antipsychotic: risperidone. Schizophr. Bull. 2002; 28: 43–61CrossRefGoogle ScholarPubMed
Davis, J.M., Matalon, L., Watanabe, M.D., Blake, L., Metalon, L.Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741–773CrossRefGoogle ScholarPubMed
Dencker, S.J., Axelsson, R.Optimising the use of depot antipsychotics. CNS Drugs 1996; 6: 367–381CrossRefGoogle Scholar
Fleischhacker, W.W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P.-M., Chrzanowski, W., et al.Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J. Clin. Psychiatry 2003; 64: 1250–1257CrossRefGoogle ScholarPubMed
Foster, R.H., Goa, K.L.Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97–133CrossRefGoogle Scholar
Gureje, O., Miles, W., Keks, N., Grainger, D., Lambert, T., McGrath, J., et al.Olanzapine vs. risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr. Res. 2003; 61: 303–314CrossRefGoogle ScholarPubMed
Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., et al.Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br. J. Psychiatry 2001; 178: 506–517CrossRefGoogle ScholarPubMed
Herrmann, N., Mamdani, M., Lanctot, K.L.Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry 2004; 161: 1113–1115CrossRefGoogle ScholarPubMed
Jolley, A.G., Hirsch, S.R., Morrison, E., McRink, A., Wilson, L.Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at 2 years. Br. Med. J. 1990; 301: 837–842CrossRefGoogle Scholar
Kane, J.M.Dosage and route of administration of neuroleptic drugs during different phases of a schizophrenic illness. Kissling, W.Guidelines for neuroleptic relapse prevention Berlin, Heidelberg: Springer-Verlag;1991.85–93CrossRefGoogle Scholar
Kane, J.M., Eerdekens, M., Lindenmayer, J.P., Keith, S.J., Lesem, M., Karcher, K.Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003; 160: 1125–1132CrossRefGoogle ScholarPubMed
Keefe, R.S., Seidman, L.J., Christensen, B.K., Hamer, R.M., Sharma, T., Sitskoorn, M.M., et al.Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 2004; 161: 985–995CrossRefGoogle ScholarPubMed
Kinon, B.J., Basson, B.R., Gilmore, J.A., Tollefson, G.D.Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 2001; 62: 92–100CrossRefGoogle Scholar
Kinross-Wright, J., Vogt, A.H., Charalampous, K.D.A new method of drug therapy. Am. J. Psychiatry 1963; 119: 779–780CrossRefGoogle ScholarPubMed
Lecrubier, Y, Benkert, O, Kasper, S. Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6-month study. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 2000.Google Scholar
Leucht, S., Pitschel-Walz, G., Abraham, D., Kissling, W.Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 1999; 35: 51–68CrossRefGoogle ScholarPubMed
Leucht, S., Wahlbeck, K., Hamann, J., Kissling, W.New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–1589CrossRefGoogle ScholarPubMed
Lieberman, J.A., Alvir, J., Geisler, S., Ramos-Lorenzi, J., Woerner, M., Novacenko, H., et al.Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994; 11: 107–118CrossRefGoogle Scholar
Love, RC, Kelly, DL, Sherr, JD. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology, Puerto Rico, 1998.Google Scholar
Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., et al.Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 2004; 161: 1334–1349CrossRefGoogle ScholarPubMed
Martyns-Yellowe, I.S.The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West Afr. J. Med. 1994; 13: 200–203Google ScholarPubMed
Meltzer, H.Y., McGurk, S.R.The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999; 25: 233–255CrossRefGoogle Scholar
Möller, H.J.Review: treatment of schizophrenia. State of the art. Eur. Arch. Psychiatry Clin. Neurosci. 1996; 246: 229–234CrossRefGoogle ScholarPubMed
Möller, H.J.Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J. Biol. Psychiatry 2000; 1: 75–91CrossRefGoogle ScholarPubMed
Möller, H.J.State of the art of drug treatment of schizophrenia and the future position of the novel atypical antipsychotics. World J. Biol. Psychiatry 2000; 1: 204–214CrossRefGoogle ScholarPubMed
Möller, H.J.Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17: 793–823CrossRefGoogle ScholarPubMed
Möller, H.J., Boyer, P., Fleurot, O., Rein, W.Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl.) 1997; 132: 396–401Google ScholarPubMed
Moore, D.B., Kelly, D.L., Sherr, J.D., Love, R.C., Conley, R.R.Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm. 1998; 55: S17–S19CrossRefGoogle ScholarPubMed
Mori, K., Nagao, M., Yamashita, H., Morinobu, S., Yamawaki, S.Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 659–665CrossRefGoogle ScholarPubMed
Nasrallah, H.A., Duchesne, I., Mehnert, A., Janagap, C., Eerdekens, M.Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J. Clin. Psychiatry 2004; 65: 531–536CrossRefGoogle ScholarPubMed
Pereira, S., Pinto, R.A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr. Scand. 1997; 95: 464–468CrossRefGoogle ScholarPubMed
Peuskens, J., Bech, P., Möller, H.J., Bale, R., Fleurot, O., Rein, W.Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999; 88: 107–117CrossRefGoogle ScholarPubMed
Puech, A., Fleurot, O., Rein, W.Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr. Scand. 1998; 98: 65–72CrossRefGoogle ScholarPubMed
Quraishi, S., David, A.Depot pipothiazine palmitate and undeclynate for schizophrenia (Cochrane review). The Cochrane Library, issue 2 Oxford: Update Software; 2001Google Scholar
Quraishi, S., David, A.Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders (Cochrane review). The Cochrane Library, issue 2 Oxford:Update Software; 2001Google Scholar
Quraishi, S., David, A.Depot haloperidol decanoate for schizophrenia (Cochrane review). The Cochrane Library, issue 2 Oxford: Update Software; 2001Google Scholar
Quraishi, S., David, A., Adams, C.E.Depot bromperidol decanoate for schizophrenia (Cochrane review). The Cochrane Library, issue 2 :Update Software; 2001Google Scholar
Quraishi, S., David, A., Adams, C.E.Depot fluspirilene for schizophrenia (Cochrane review). The Cochrane Library, issue 2 Oxford:Update Software; 2001Google Scholar
Rabinowitz, J., Lichtenberg, P., Kaplan, Z., Mark, M., Nahon, D., Davidson, M.Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am. J. Psychiatry 2001; 158: 266–269CrossRefGoogle ScholarPubMed
Sharma, T.Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br. J. Psychiatry 38Suppl1999 44–51CrossRefGoogle Scholar
Simpson, G.M., Lindenmayer, J.P.Extrapyramidal symptoms in patients treated with risperidone. J. Clin. Psychopharmacol. 1997; 17: 194–201CrossRefGoogle ScholarPubMed
Speller, J.C., Barnes, T.R., Curson, D.A., Pantelis, C., Alberts, J.L.One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride vs. haloperidol. Br. J. Psychiatry 1997; 171: 564–568CrossRefGoogle Scholar
Tattan, T.M., Creed, F.H.Negative symptoms of schizophrenia and compliance with medication. Schizophr. Bull. 2001; 27: 149–155CrossRefGoogle ScholarPubMed
Tollefson, G.D., Beasley, , Jr, C.M., Tran, P.V., Street, J.S., Krueger, J.A., Tamura, R.N., et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997; 154: 457–465Google ScholarPubMed
Tran, P.V., Hamilton, S.H., Kuntz, A.J., Potvin, J.H., Andersen, S.W., Beasley, , Jr, C., et al.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997; 17: 407–418CrossRefGoogle ScholarPubMed
Tuninger, E., Levander, S.Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatr. Scand. 1997; 96: 347–353CrossRefGoogle ScholarPubMed
Vasavan Nair, N.P., Suranyi-Cadotte, B., Schwartz, G., Thavundayil, J.X., Achim, A., Lizondo, E., et al.A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J. Clin. Psychopharmacol. 1986; 6: 30S–37SCrossRefGoogle ScholarPubMed
Voruganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S., Awad, A.Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 2000; 43: 135–145CrossRefGoogle ScholarPubMed
Walburn, J., Gray, R., Gournay, K., Quraishi, S., David, A.S.Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br. J. Psychiatry 2001; 179: 300–307CrossRefGoogle ScholarPubMed
Weiden, P., Aquila, R., Standard, J.Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry 57Suppl 111996 53–60Google Scholar
Youssef, H.A.Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clin. Neuropharmacol. 14Suppl 21991 S16–S21Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.